Skip to content

US · BLCO · MEDICAL - INSTRUMENTS & SUPPLIES

Bausch + Lomb Corporation (BLCO) intrinsic value and stock valuation

$19.38as of 2026-11-21 · Mkt cap 5.99B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Bausch + Lomb Corporation DCF and intrinsic value

InvestorsCraft values BLCO with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from BLCO’s statements →

Bausch + Lomb Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Vaughan, ON L4K 4B4 bausch.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$5.1B+8.4% 5y CAGRd
20182025
Net income
-$-360M
20182025
Free cash flow
-$-66M
20182025
Total equity
$6.52B-8.2% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$5.1B$4.79B$4.15B$3.77B$3.77B
Operating income$188M$162M$130M$207M$329M
Net income-$-360M-$-317M-$-260M$6M$182M
EPSd-$-1.02M-$-901.08K-$-741.8K$17.1K$520K
Operating cash flow$283M$232M-$-17M$345M$873M
Capital expenditure-$-349M-$-291M-$-181M-$-175M-$-193M
Free cash flow-$-66M-$-59M-$-198M$170M$680M
Total assets$14B$13.5B$13.4B$11.1B$10.8B
Total debt$5.37B$4.94B$4.68B$2.55B$140M
Net debt$4.99B$4.63B$4.34B$2.17B-$-34M
Total equity$6.52B$6.54B$6.92B$7.1B$9.4B
Cash and short-term investments$383M$305M$334M$380M$174M
Income statement
20252024202320222021
Revenue$5.1B$4.79B$4.15B$3.77B$3.77B
Cost of revenue$2.31B$1.87B$1.64B$1.52B$1.47B
Gross profit$2.79B$2.92B$2.5B$2.25B$2.3B
Research and development expenses$371M$343M$324M$307M$271M
Selling, general and administrative expenses$2.23B$2.08B$1.74B$1.48B$1.39B
Other expenses$0.00$332M$314M$257M$309M
Operating expenses$2.61B$2.76B$2.37B$2.04B$1.97B
Cost and expenses$4.91B$4.63B$4.02B$3.56B$3.44B
Interest income$12M$15M$15M$6M$0.00
Interest expense$431M$399M$283M$146M$0.00
Depreciation and amortization$421M$436M$382M$379M$415M
Ebitda$535M$601M$499M$598M$733M
Operating income$188M$162M$130M$207M$329M
Total other income/expenses, net-$-505M-$-396M-$-296M-$-134M-$-11M
Income before tax-$-317M-$-234M-$-166M$73M$318M
Income tax expense$35M$71M$82M$58M$125M
Net income-$-360M-$-317M-$-260M$6M$182M
Weighted average shares outstanding$353.8M$351.8M$350.5M$350M$350M
Weighted average diluted shares outstanding$353.8M$351.8M$350.5M$350M$350M
Balance sheet
20252024202320222021
Cash and short-term investments$383M$305M$334M$380M$174M
Net receivables$1.22B$1.03B$875M$726M$721M
Inventory$976M$1.04B$1.03B$628M$572M
Total current assets$2.98B$2.79B$2.74B$2.14B$1.64B
Property, plant and equipment, net$1.76B$1.49B$1.5B$1.42B$1.23B
Goodwill and intangible assets$8.04B$8.02B$8.16B$6.57B$6.85B
Long-term investments$7M$19M$19M$12M$0.00
Total non-current assets$11B$10.7B$10.7B$9.01B$9.19B
Total assets$14B$13.5B$13.4B$11.1B$10.8B
Accounts payable$388M$389M$522M$317M$239M
Short-term debt$77M$72M$57M$51M$48M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.92B$1.74B$1.58B$1.3B$1.1B
Long-term debt$5.29B$4.86B$4.62B$2.5B$92M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$5.58B$5.19B$4.94B$2.75B$322M
Capital lease obligations$125M$152M$87M$92M$112M
Total liabilities$7.5B$6.93B$6.52B$4.04B$1.42B
Common stock$0.00$0.00$0.00$0.00$10.4B
Retained earnings-$-931M-$-571M-$-254M$6M$0.00
Accumulated other comprehensive income (loss)-$-1.18B-$-1.39B-$-1.25B-$-1.26B-$-1.04B
Total equity$6.52B$6.54B$6.92B$7.1B$9.4B
Total investments$7M$19M$19M$12M$0.00
Total debt$5.37B$4.94B$4.68B$2.55B$140M
Net debt$4.99B$4.63B$4.34B$2.17B-$-34M
Cash flow statement
20252024202320222021
Net income-$-352M-$-305M-$-248M$15M$193M
Depreciation and amortization$421M$436M$382M$379M$415M
Stock-based compensation$149M$92M$74M$62M$62M
Change in working capital$18M-$-87M-$-287M-$-19M$28M
Accounts receivable-$-148M-$-227M-$-121M-$-95M-$-107M
Inventory$38M-$-147M-$-264M-$-106M-$-15M
Accounts payable$108M$126M$245M$189M$163M
Net cash provided by operating activities$283M$232M-$-17M$345M$873M
Investments in property, plant and equipment-$-349M-$-291M-$-181M-$-175M-$-193M
Acquisitions, net$0.00$0.00-$-1.94B$45M-$-16M
Net cash used for investing activities-$-455M-$-412M-$-2.11B-$-215M-$-214M
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased$0.00-$-12M$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$225M$178M$2.08B$81M-$-712M
Net change in cash$81M-$-18M-$-46M$203M-$-61M
Cash at end of period$397M$316M$334M$380M$177M
Operating cash flow$283M$232M-$-17M$345M$873M
Capital expenditure-$-349M-$-291M-$-181M-$-175M-$-193M
Free cash flow-$-66M-$-59M-$-198M$170M$680M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Bausch + Lomb Corporation

        Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.

        CEO
        Brenton L. Saunders
        Employees
        13K
        Beta
        0.56

        Explore

        Frequently asked questions

        What is the intrinsic value of Bausch + Lomb Corporation (BLCO)?

        Bausch + Lomb Corporation (BLCO) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is BLCO undervalued?

        BLCO trades at a price of $19.38 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.